APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Industry Research

Opioid Receptor Agonist Industry Research Report 2026

29 December 2025139 pages

Choose your research edition.

Industry ResearchOpioid Receptor Agonist Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Receptor Agonist Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Receptor Agonist Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Receptor Agonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Opioid Receptor Agonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Opioid Receptor Agonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Opioid Receptor Agonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Opioid Receptor Agonist include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Opioid Receptor Agonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Opioid Receptor Agonist Market by Company

Allergan

DAIICHI SANKYO COMPANY

Endo Pharmaceuticals

Fresenius Kabi

Hikma Pharmaceuticals

Indivior

Mylan N.V.

Piramal Critical Care

Purdue Pharma

Sun Pharmaceutical Industries

Tris Pharma

US WorldMeds

Pfizer

Johnson & Johnson

Teva Pharmaceutical Industries

Opioid Receptor Agonist Segment by Type

Morphine

Codeine

Fentanyl

Others

Opioid Receptor Agonist Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Opioid Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Opioid Receptor Agonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Opioid Receptor Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Opioid Receptor Agonist Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Opioid Receptor Agonist Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Opioid Receptor Agonist Sales Market Share by Manufacturers (2021-2026) Table 8. Global Opioid Receptor Agonist Revenue of Manufacturers (2021-2026) Table 9. Global Opioid Receptor Agonist Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Opioid Receptor Agonist Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Opioid Receptor Agonist Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Opioid Receptor Agonist, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Opioid Receptor Agonist, Product Type & Application Table 14. Global Opioid Receptor Agonist Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Opioid Receptor Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Allergan Company Information Table 19. Allergan Business Overview Table 20. Allergan Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Allergan Opioid Receptor Agonist Product Portfolio Table 22. Allergan Recent Developments Table 23. DAIICHI SANKYO COMPANY Company Information Table 24. DAIICHI SANKYO COMPANY Business Overview Table 25. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio Table 27. DAIICHI SANKYO COMPANY Recent Developments Table 28. Endo Pharmaceuticals Company Information Table 29. Endo Pharmaceuticals Business Overview Table 30. Endo Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 32. Endo Pharmaceuticals Recent Developments Table 33. Fresenius Kabi Company Information Table 34. Fresenius Kabi Business Overview Table 35. Fresenius Kabi Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Fresenius Kabi Opioid Receptor Agonist Product Portfolio Table 37. Fresenius Kabi Recent Developments Table 38. Hikma Pharmaceuticals Company Information Table 39. Hikma Pharmaceuticals Business Overview Table 40. Hikma Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 42. Hikma Pharmaceuticals Recent Developments Table 43. Indivior Company Information Table 44. Indivior Business Overview Table 45. Indivior Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Indivior Opioid Receptor Agonist Product Portfolio Table 47. Indivior Recent Developments Table 48. Mylan N.V. Company Information Table 49. Mylan N.V. Business Overview Table 50. Mylan N.V. Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Mylan N.V. Opioid Receptor Agonist Product Portfolio Table 52. Mylan N.V. Recent Developments Table 53. Piramal Critical Care Company Information Table 54. Piramal Critical Care Business Overview Table 55. Piramal Critical Care Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Piramal Critical Care Opioid Receptor Agonist Product Portfolio Table 57. Piramal Critical Care Recent Developments Table 58. Purdue Pharma Company Information Table 59. Purdue Pharma Business Overview Table 60. Purdue Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Purdue Pharma Opioid Receptor Agonist Product Portfolio Table 62. Purdue Pharma Recent Developments Table 63. Sun Pharmaceutical Industries Company Information Table 64. Sun Pharmaceutical Industries Business Overview Table 65. Sun Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 67. Sun Pharmaceutical Industries Recent Developments Table 68. Tris Pharma Company Information Table 69. Tris Pharma Business Overview Table 70. Tris Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Tris Pharma Opioid Receptor Agonist Product Portfolio Table 72. Tris Pharma Recent Developments Table 73. US WorldMeds Company Information Table 74. US WorldMeds Business Overview Table 75. US WorldMeds Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. US WorldMeds Opioid Receptor Agonist Product Portfolio Table 77. US WorldMeds Recent Developments Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Opioid Receptor Agonist Product Portfolio Table 82. Pfizer Recent Developments Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Opioid Receptor Agonist Product Portfolio Table 87. Johnson & Johnson Recent Developments Table 88. Teva Pharmaceutical Industries Company Information Table 89. Teva Pharmaceutical Industries Business Overview Table 90. Teva Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 92. Teva Pharmaceutical Industries Recent Developments Table 93. Global Opioid Receptor Agonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Opioid Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 95. Global Opioid Receptor Agonist Sales Market Share by Region (2021-2026) Table 96. Global Opioid Receptor Agonist Sales by Region (2027-2032) & (K Units) Table 97. Global Opioid Receptor Agonist Sales Market Share by Region (2027-2032) Table 98. Global Opioid Receptor Agonist Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2026) Table 100. Global Opioid Receptor Agonist Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Opioid Receptor Agonist Revenue Market Share by Region (2027-2032) Table 102. North America Opioid Receptor Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 104. North America Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 105. North America Opioid Receptor Agonist Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Opioid Receptor Agonist Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Opioid Receptor Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 109. Europe Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 110. Europe Opioid Receptor Agonist Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Opioid Receptor Agonist Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Opioid Receptor Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Opioid Receptor Agonist Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Opioid Receptor Agonist Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Opioid Receptor Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 119. South America Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 120. South America Opioid Receptor Agonist Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Opioid Receptor Agonist Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Opioid Receptor Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Opioid Receptor Agonist Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Opioid Receptor Agonist Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 128. Global Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 129. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2026) Table 130. Global Opioid Receptor Agonist Sales Market Share by Type (2027-2032) Table 131. Global Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2026) Table 134. Global Opioid Receptor Agonist Revenue Market Share by Type (2027-2032) Table 135. Global Opioid Receptor Agonist Price by Type (2021-2026) & (US$/Unit) Table 136. Global Opioid Receptor Agonist Price by Type (2027-2032) & (US$/Unit) Table 137. Global Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 138. Global Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 139. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2026) Table 140. Global Opioid Receptor Agonist Sales Market Share by Application (2027-2032) Table 141. Global Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2026) Table 144. Global Opioid Receptor Agonist Revenue Market Share by Application (2027-2032) Table 145. Global Opioid Receptor Agonist Price by Application (2021-2026) & (US$/Unit) Table 146. Global Opioid Receptor Agonist Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Opioid Receptor Agonist Distributors List Table 150. Opioid Receptor Agonist Customers List Table 151. Opioid Receptor Agonist Industry Trends Table 152. Opioid Receptor Agonist Industry Drivers Table 153. Opioid Receptor Agonist Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Opioid Receptor Agonist Product Image Figure 5. Global Opioid Receptor Agonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Opioid Receptor Agonist Market Size (2021-2032) & (US$ Million) Figure 7. Global Opioid Receptor Agonist Sales (2021-2032) & (K Units) Figure 8. Global Opioid Receptor Agonist Average Price (US$/Unit) & (2021-2032) Figure 9. Morphine Product Image Figure 10. Codeine Product Image Figure 11. Fentanyl Product Image Figure 12. Others Product Image Figure 13. Retail Pharmacy Product Image Figure 14. Online Pharmacy Product Image Figure 15. Hospital Pharmacy Product Image Figure 16. Global Opioid Receptor Agonist Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Opioid Receptor Agonist, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Opioid Receptor Agonist Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Opioid Receptor Agonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Opioid Receptor Agonist Sales by Region in 2025 Figure 22. Global Opioid Receptor Agonist Revenue by Region in 2025 Figure 23. North America Opioid Receptor Agonist Market Size by Country in 2025 Figure 24. North America Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 25. North America Opioid Receptor Agonist Revenue Market Share by Country (2021-2032) Figure 26. United States Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Opioid Receptor Agonist Market Size by Country in 2025 Figure 29. Europe Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 30. Europe Opioid Receptor Agonist Revenue Market Share by Country (2021-2032) Figure 31. Germany Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Opioid Receptor Agonist Market Size by Country in 2025 Figure 37. Asia Pacific Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Opioid Receptor Agonist Revenue Market Share by Country (2021-2032) Figure 39. China Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Opioid Receptor Agonist Market Size by Country in 2025 Figure 48. South America Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 49. South America Opioid Receptor Agonist Revenue Market Share by Country (2021-2032) Figure 50. Mexico Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Opioid Receptor Agonist Market Size by Country in 2025 Figure 54. Middle East and Africa Opioid Receptor Agonist Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Opioid Receptor Agonist Revenue Market Share by Country (2021-2032) Figure 56. Turkey Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Opioid Receptor Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032) Figure 60. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032) Figure 61. Global Opioid Receptor Agonist Price (US$/Unit) by Type (2021-2032) Figure 62. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032) Figure 63. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032) Figure 64. Global Opioid Receptor Agonist Price (US$/Unit) by Application (2021-2032) Figure 65. Opioid Receptor Agonist Value Chain Figure 66. Opioid Receptor Agonist Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Opioid Receptor Agonist Industry Opportunities and Challenges

Scope & coverage.

Types
  • Morphine
  • Codeine
  • Fentanyl
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Allergan
  • DAIICHI SANKYO COMPANY
  • Endo Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Indivior
  • Mylan N.V.
  • Piramal Critical Care
  • Purdue Pharma
  • Sun Pharmaceutical Industries
  • Tris Pharma
  • US WorldMeds
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceutical Industries

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Opioid Receptor Agonist Market Size (2021-2032)
  4. 2.2.2 Global Opioid Receptor Agonist Sales (2021-2032)
  5. 2.2.3 Global Opioid Receptor Agonist Market Average Price (2021-2032)
  6. 2.3 Opioid Receptor Agonist by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Morphine
  9. 2.3.3 Codeine
  10. 2.3.4 Fentanyl
  11. 2.3.5 Others
  12. 2.4 Opioid Receptor Agonist by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Retail Pharmacy
  15. 2.4.3 Online Pharmacy
  16. 2.4.4 Hospital Pharmacy
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Opioid Receptor Agonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Opioid Receptor Agonist Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Opioid Receptor Agonist Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Opioid Receptor Agonist Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Opioid Receptor Agonist Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Opioid Receptor Agonist, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Opioid Receptor Agonist, Product Type & Application
  8. 3.8 Global Manufacturers of Opioid Receptor Agonist, Established Date
  9. 3.9 Global Opioid Receptor Agonist Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Allergan
  2. 4.1.1 Allergan Company Information
  3. 4.1.2 Allergan Business Overview
  4. 4.1.3 Allergan Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Allergan Opioid Receptor Agonist Product Portfolio
  6. 4.1.5 Allergan Recent Developments
  7. 4.2 DAIICHI SANKYO COMPANY
  8. 4.2.1 DAIICHI SANKYO COMPANY Company Information
  9. 4.2.2 DAIICHI SANKYO COMPANY Business Overview
  10. 4.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
  12. 4.2.5 DAIICHI SANKYO COMPANY Recent Developments
  13. 4.3 Endo Pharmaceuticals
  14. 4.3.1 Endo Pharmaceuticals Company Information
  15. 4.3.2 Endo Pharmaceuticals Business Overview
  16. 4.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  18. 4.3.5 Endo Pharmaceuticals Recent Developments
  19. 4.4 Fresenius Kabi
  20. 4.4.1 Fresenius Kabi Company Information
  21. 4.4.2 Fresenius Kabi Business Overview
  22. 4.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
  24. 4.4.5 Fresenius Kabi Recent Developments
  25. 4.5 Hikma Pharmaceuticals
  26. 4.5.1 Hikma Pharmaceuticals Company Information
  27. 4.5.2 Hikma Pharmaceuticals Business Overview
  28. 4.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  30. 4.5.5 Hikma Pharmaceuticals Recent Developments
  31. 4.6 Indivior
  32. 4.6.1 Indivior Company Information
  33. 4.6.2 Indivior Business Overview
  34. 4.6.3 Indivior Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Indivior Opioid Receptor Agonist Product Portfolio
  36. 4.6.5 Indivior Recent Developments
  37. 4.7 Mylan N.V.
  38. 4.7.1 Mylan N.V. Company Information
  39. 4.7.2 Mylan N.V. Business Overview
  40. 4.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
  42. 4.7.5 Mylan N.V. Recent Developments
  43. 4.8 Piramal Critical Care
  44. 4.8.1 Piramal Critical Care Company Information
  45. 4.8.2 Piramal Critical Care Business Overview
  46. 4.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
  48. 4.8.5 Piramal Critical Care Recent Developments
  49. 4.9 Purdue Pharma
  50. 4.9.1 Purdue Pharma Company Information
  51. 4.9.2 Purdue Pharma Business Overview
  52. 4.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
  54. 4.9.5 Purdue Pharma Recent Developments
  55. 4.10 Sun Pharmaceutical Industries
  56. 4.10.1 Sun Pharmaceutical Industries Company Information
  57. 4.10.2 Sun Pharmaceutical Industries Business Overview
  58. 4.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  60. 4.10.5 Sun Pharmaceutical Industries Recent Developments
  61. 4.11 Tris Pharma
  62. 4.11.1 Tris Pharma Company Information
  63. 4.11.2 Tris Pharma Business Overview
  64. 4.11.3 Tris Pharma Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
  66. 4.11.5 Tris Pharma Recent Developments
  67. 4.12 US WorldMeds
  68. 4.12.1 US WorldMeds Company Information
  69. 4.12.2 US WorldMeds Business Overview
  70. 4.12.3 US WorldMeds Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
  72. 4.12.5 US WorldMeds Recent Developments
  73. 4.13 Pfizer
  74. 4.13.1 Pfizer Company Information
  75. 4.13.2 Pfizer Business Overview
  76. 4.13.3 Pfizer Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
  78. 4.13.5 Pfizer Recent Developments
  79. 4.14 Johnson & Johnson
  80. 4.14.1 Johnson & Johnson Company Information
  81. 4.14.2 Johnson & Johnson Business Overview
  82. 4.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
  84. 4.14.5 Johnson & Johnson Recent Developments
  85. 4.15 Teva Pharmaceutical Industries
  86. 4.15.1 Teva Pharmaceutical Industries Company Information
  87. 4.15.2 Teva Pharmaceutical Industries Business Overview
  88. 4.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  90. 4.15.5 Teva Pharmaceutical Industries Recent Developments
5 Global Opioid Receptor Agonist Market Scenario by Region
  1. 5.1 Global Opioid Receptor Agonist Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Opioid Receptor Agonist Sales by Region: 2021-2032
  3. 5.2.1 Global Opioid Receptor Agonist Sales by Region: 2021-2026
  4. 5.2.2 Global Opioid Receptor Agonist Sales by Region: 2027-2032
  5. 5.3 Global Opioid Receptor Agonist Revenue by Region: 2021-2032
  6. 5.3.1 Global Opioid Receptor Agonist Revenue by Region: 2021-2026
  7. 5.3.2 Global Opioid Receptor Agonist Revenue by Region: 2027-2032
  8. 5.4 North America Opioid Receptor Agonist Market Facts & Figures by Country
  9. 5.4.1 North America Opioid Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Opioid Receptor Agonist Sales by Country (2021-2032)
  11. 5.4.3 North America Opioid Receptor Agonist Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Opioid Receptor Agonist Market Facts & Figures by Country
  15. 5.5.1 Europe Opioid Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Opioid Receptor Agonist Sales by Country (2021-2032)
  17. 5.5.3 Europe Opioid Receptor Agonist Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Opioid Receptor Agonist Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Opioid Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Opioid Receptor Agonist Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Opioid Receptor Agonist Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Opioid Receptor Agonist Market Facts & Figures by Country
  35. 5.7.1 South America Opioid Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Opioid Receptor Agonist Sales by Country (2021-2032)
  37. 5.7.3 South America Opioid Receptor Agonist Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Opioid Receptor Agonist Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Opioid Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Opioid Receptor Agonist Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Opioid Receptor Agonist Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Opioid Receptor Agonist Sales by Type (2021-2032)
  2. 6.1.1 Global Opioid Receptor Agonist Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032)
  4. 6.2 Global Opioid Receptor Agonist Revenue by Type (2021-2032)
  5. 6.2.1 Global Opioid Receptor Agonist Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Opioid Receptor Agonist Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Opioid Receptor Agonist Sales by Application (2021-2032)
  2. 7.1.1 Global Opioid Receptor Agonist Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032)
  4. 7.2 Global Opioid Receptor Agonist Revenue by Application (2021-2032)
  5. 7.2.1 Global Opioid Receptor Agonist Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Opioid Receptor Agonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Opioid Receptor Agonist Value Chain Analysis
  2. 8.1.1 Opioid Receptor Agonist Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Opioid Receptor Agonist Production Mode & Process
  5. 8.2 Opioid Receptor Agonist Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Opioid Receptor Agonist Distributors
  8. 8.2.3 Opioid Receptor Agonist Customers
9 Global Opioid Receptor Agonist Analyzing Market Dynamics
  1. 9.1 Opioid Receptor Agonist Industry Trends
  2. 9.2 Opioid Receptor Agonist Industry Drivers
  3. 9.3 Opioid Receptor Agonist Industry Opportunities and Challenges
  4. 9.4 Opioid Receptor Agonist Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst